Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders
LUMOSA Board of Directors not to proceed with the
private placement of ordinary shares approved by the 2021
annual general meeting of shareholders
Date of events
2022/04/22
To which item it meets
paragraph 16
Statement
1.Date of the board of directors resolution for the change:2022/04/22
2.Effective registration date of the original plan:NA
3.Resolution date of additional issuance:NA
4.Major change Reason for the change:
On July 7, 2021, the annual shareholders meeting resolved the proposal for a
cash capital increase through private placement to issue no more than
60,000,000 common shares; the shares will be issued once or twice in sequence
within one year to complete the capital increase from the date of the
resolution of the shareholders meeting. Due to the approaching deadline, this
private placement has not yet been issued, so the board of directors decided
on April 22, 2022 that the private placement will not continue within the
remaining time limit.
5.Content of each and every successive previously changed
plan for raising of funds before and after change:NA
6.Projected timetable for execution:NA
7.Projected completion date:NA
8.Projected possible benefits:NA
9.Difference from original projected benefits:NA
10.Effect of the current change on shareholder equity:NA
11.Abstract of the original lead underwriter's appraisal opinion:NA
12.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lumosa Therapeutics Co. Ltd. published this content on 22 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 April 2022 08:07:01 UTC.
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders
LUMOSA THERAPEUTICS CO., LTD. 
